Levomilnacipran

Levomilnacipran
Klinički podaci

Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	12 h
Izlučivanje	Renalno (58%)

Identifikatori
CAS broj	96847-55-1^Y
ATC kod	None
PubChem	CID 65833
DrugBank	DB08918^Y
Hemijski podaci
SMILES CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2

Levomilnacipran je selektivni serotonin i norepinefrinski resorptivni inhibitor. Hemijski, levomilnacipran je 1S,2R-enantiomer milnaciprana. FDA ga je priznala 25. jula 2013. godine.^[1]^[2]

Reference

^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.